Each haemodialysis treatment requires the application of anticoagulation medicines, which will prevent coagulation in extracorporal blood circulation. In this study we try to determine the quality of admitted anticoagulant and his eff ect on lipid profi le on hemodialysis patients after twelth months. We were applying standard heparin and low weight molecular heparin (LWMH). During our study we was analyzed eff ect of anticoagulant therapy on lipid profi le of hemodialysis patients. In that parameters was included triglycerides, cholesterol, lipoprotein fractions, complete blood count, Hgb, HCT; All of these parameters was analyzed in correlation with duration of hemodialysis treatment, sex and age of the patients. Our research was carried out as a prospective study, for the period of  months. In the study were included  patients (M/F), who were on chronic hemodialysis program. All patients were divided into two groups. e fi rst group of patients was included  patients (M/F) who were treated with standard heparin. e second group was included  patients (M/F) treated with LWMH (enoxaparin). e average length of hemodialysis was , ± , years. Each patient had a protocol in which is marked parameters such as fl ushing diallysator, creating fi brin-ring in vein and arterial dropper and the time it takes to stop the bleeding. In the results the average age amounted to , ± , years. e average value of cholesterol in the blood was , ± ,. Values of HDL-cholesterol in patients treated with LWMH were signifi cantly lower (P≤,) in the treated group compared to standard heparin. ere were no signifi cant statistical diff erences between both groups in relation to the level of LDL cholesterol in the blood. (p ns). LWMH had a better eff ect on the irrigation system and dialysator on both sex equally, compared with standard heparin. LWMH is in the female dialysis population has led to improvements in lipid profi le. After the fi rst six months of study in male patients treated with standard heparin in relation to the female part of the observed patients was signifi cantly better anticoagulation eff ect in the fi rst half of the study (, ± , compared to , ± ,) (P≤,). Average rating blood clots were statistically signifi cant for standard heparin (p≤,) with , at the beginning the value is fell to ,, while for LWMH with , at the beginning of the study amounted to , grade average. (P≤, ). e results of our study show that LWMH had a better rinsing eff ect of dialysis systems and dialysator in both sex equally, compared to standard unfractioned heparin. When
Introduction
Hemodialysis and continuous renal function replacement techniques require removal of blood outside of the body in extra corporal circulation for process of blood purifying and filtration. To prevent blood coagulation during hemodialysis in treatment we must include anticoagulation therapy, (usually give heparin). After hemodialysis treatment we monitoring parameters INR and APTT which enables proper dosage of given anticoagulant in therapy. Determination of APTT and INR has the advantage compared to determine the total time for blood clotting and simple methods for very rapid interpretation of results. Generally, many dialysis centers do not routinely determine the parameters of anticoagulation until you reach certain complications such as clots in dialysator and dialysis system, or prolonged bleeding time in patients after HD. In order to reduce the risk of bleeding after HD treatment, in dialysis centers give the lowest dose of heparin to patients which is sufficient to make complete hemodialysis treatment without fear that there will be coagulation or cloth formations of blood in dialysator, artherial or vein dropper, or in the system. Anticoagulation in hemodialysis treatment is performed using low weight molecular heparin (LMWH) that was proposed in order to reduce complications of bleeding and reduce the appearance of thrombocytopenia, such as complications that is present with the treatment of standard heparin. Also, LWMH it was had better eff ects on lipid profi le on hemodialysis patients. However, numerous randomized studies have shown that differences between LWMH and standard heparin is almost minimal.
Aim
The aim of this work was to evaluate effects of standard heparin and Low Weight Molecular Heparin (LWMH) on the level of triglycerides, cholesterol, lipoproteins on hemodialysis patients and their anticoagulant effect, and relation this parameters on sex and age of patients, as well as examining the correlation between the length of HD and age of the patients.
Materials and Methods

Patients
In this study were included  patients ( men and  women), which are on chronic hemodialysis program for the period longest than six months, with a different etiology of renal disease. All subjects were divided into two groups.
e fi rst group of respondents,  of them was treated with standard heparin. In this group the sexual distribution was  men and  women. The average age for women was ., while the men amounted to  years; the average length of hemodialysis was , ± , years. Application heparin was done continuously during the HD (the pump is programmed to stop the car  minutes before the end of HD treatment)
The second group of  subjects were constituted treated with low-heparin (LWMH). In this group there were  men (,) and  women (,). The average age was , ± , years. The average age for men was ,, while for women amounted to , years. The average length of hemodialysis was , ± , years. Low-heparin was given at the beginning hemodialysis treatment in a dose subcutaneous particularly adapted to each patient. Methods e survey lasted twelve months; data from the completion of laboratory tests were taken every three months during the study, were then grouped into half-yearly results and for the period January-June and July to December. Patients were on HD three times a week by four hours (bicarbonate dialysis), low-fl ux dialysate, dialysis monitors of fi rm Fresenius Medical Care, S with UF.
e research was conducted at the Clinic for hemodialysis, and Institute of Clinical Chemistry and Biochemistry. It was a retrospective prospective controlled study. Standard heparin was applied in doses of  to  UI/kg and on continuously (on average from  to  UI for four hours duration of hemodialysis). Low-heparin it was enoxaparin (Clexan) in a dose of  mg, which was gave in a single dose in the arterial part of the dialysis system. Also considered were taken and data personal history, family history and co morbid conditions. Blood coagulation a test was taken from arterial dialysis lines, front seats heparin infusion, so the test refl ects the state of the system of patient's anticoagulation. Rinse dialysator shows how many of capillary is coagulating (so that the counting of the number of coagulating capillaries performed the evaluation).
Statistical analysis
Results were statistically analyzed to determine average value (x), standard deviation (SD) and standard error mean (SEM) for each monitored parameter within the group. Differences between the values determined by Student t-test and chisquare test (χ). Values less than , taken as significant. Correlation between compared parameters determined by Spearman-in, Wilcox's method.
Results
e research was conducted on  subjects for a period of twelve months. All subjects were on chronic hemodialysis program in more than six months, with a diff erent cause of chronic kidney misfi re. All subjects were divided into two groups. e fi rst group of consisted of  subjects treated with standard heparin, and another group of consisted of  subjects treated with LMWH. Laboratory analysis of the findings of blood was performed every three months during one year how much time research. Data obtained were analyzed as data and information at the beginning of the end of the study. From chart  we can note that the women are on average older age than men and in both examined groups. Total number of age for men in the standard heparin treated group was , years and women  years. Average age for men in the group treated with lowheparin was ,, while for women the same age group the average amounted to , years. e causes that led to chronic renal failure in our patients were varied. Nephroangisclerosis is the leading cause and participate with , in the etiology of chronic renal failure, followed by urinary obstruction for the following times , while the hereditary renal diseases participated with ,.
HALIMA RESIĆ ET AL.: DIFFERENT EFFECTS OF LOW WEIGHT MOLECULAR HEPARIN AND UNFRACTIONED HEPARIN ON LIPID PROFILE AND COAGULATION AT HAEMODIALYSIS PATIENTS
Rate heparin for blood clots in both the years for men and women was not significant.
From the Table  . we see that for the second period of monitoring (from July to December .) subjects who received heparin in the second half had a statistically significant decrease evaluate of blood clots compared to patients who received enoxaparin, which means better flushing of hemodialysis systems, and arterial and vein dropper.
The result of testing the found in the average evaluation of blood clots shown in the der was statistically mainly negative, while the following year, the diff erence is more pronounced. (Table ) .
Discussion
Atherosclerotic changes on hemodialysis patients are multifactor conditioned. at's the causes of increased of morbidity and mortality in dialysis population. One of risk factor is hyperlipidemia, which accelerates atherosclerosis and which also leading to increase prevalence of cardiovascular disease and the increases of mortality in hemodialysis population. Dyslipidemia, is primarily mean increased values of triglycerides in the blood and decrease levels of "protective" HDL-cholesterol and increase levels of low-density lipoprotein (LDL), which operate jointly with disorders in blood coagulation and metabolic disorders. In our dialysis population increased levels of triglyceride in the blood iwas  of patients at the beginning of the study. Characteristics of uremic dyslipidemia were hypertriglyceridemia, the increase of the remaining lipoprotein (remaining Chylomicron and IDL-a), reduced HDL-cholesterol, and increase in SD-LDL, Lp (a) and ApoA-IV.() Control of these parameters was performed in our clinic every three months. At the beginning of the study was observed elevated levels of LDL cholesterol by  of respondents. Total LDL cholesterol levels was often normal in chronic renal disease and patients which was on chronic hemodialysis treatment, but is usually found elevated levels sdLDL, IDL, LDL, which are probably more atherogenic. Equally, clinical studies do not distinguish between LDL-A, Lp (a) and their LWMH isoform, which are independent risk factors for atherosclerotic disease and are often elevated in chronic kidney disease, but analysis of these isoform was technically managed for our study. IDL cholesterol is often elevated in uremia. Unfortunately, current clinical trials do not distinguish between LDL cholesterol and IDL cholesterol. erefore, some clinical trials may not assess the emergence atherosclerosis exact cholesterol loaded in uremia. () Our study also has not been specifi cally processed IDL cholesterol. Influence of LWMH heparin and standard heparin on the concentration of total cholesterol showed no signifi cant statistical diff erence at the end of our research. While studies have not noticed favorable eff ects LWMH and standard heparin on the concentration of total cholesterol in plasma for both groups of respondents. LWMH was no showed expected lipolitycal eff ect, coincides with the results of research he spent Kronenberg et al. () e fact that the low-heparin showed minor diff erences according to gender through the same treatment period than is the case with standard heparin. Even his infl uence and the eff ect are more favorable with the male part of the tested population, but women throughout the period of follow-up study. However, enoxaparin showed mainly negative decline in the level of HDL cholesterol at the end of the study, which was not expected, nor was positive for patients. Standard heparin showed no signifi cant deviations from the beginning until the end of the study spent. e difference to the sexual distribution of standard heparin was signifi cant and gave better results in men than in women's part of respondents. Influence of standard heparin on LDL cholesterol is such that the mean value of , down to , which is positive, also came up with the fall of HDL cholesterol values of , to , in the second period which is not favorable effect, but it was expected, also comes treiglicerida to fall with the value , to the value of , which is also a positive eff ect but he was not expected. In cross-study conducted by Deuber and Schulz () was showed data were taken from fi ve patients who received standard heparin, LMWH after a period of  months, then again returned to standard heparin, While receiving LMWH, there was a signifi cant reduction of the concentration of triglycerides and cholesterol in the blood, In other studies, cholesterol values were decreased between - in the period of treatment with LMWH for a period of monitoring from  to  months (, ), however, while there was no change in the value of cholesterol in the course of giving LMWH, which is followed in the study by Schrader spent and out, As also coincides with our study () , Eff ect of LWMH is slightly diff erent and its infl uence on HDL cholesterol in the fi rst period of investigation amounted to ,, while for the second period of monitoring of its high value of , was statistically signifi cant and unexpected diff erences. ere are not mainly negative values decrease LDL cholesterol values from , to ,, which is expected and good, but should be much higher. LWMH effect on triglyceride levels that are in the fi rst six months of the study had a value of , to the second period, at the end of the study had a value of ,, which is expected and positive for our respondents. Standard heparin in the fi rst six months of research showed slightly better eff ect on lowering levels of triglycerides in the blood, but the twelve months to the value of the individual subjects and showed a slight increase (at  patients). (, ) Compared with the study conducted by Lieu and authors, () showed how LMWH has less affi nity for LPL, which has not resulted in reduced potency to the release of LPL-and, by endothelial carried in peripheral tissues, but primarily in substantially reduced effect in terms of hepatical removal of this enzyme. From a theoretical standpoint there is a possibility to switch from standard heparin in LWMH will not reduce triglyceride levels, as shown by Schmitt and Schneider's. () . Target values for plasma lipids in patients with chronic renal disease and dialysis patients are unknown. Clinical studies the most commonly used for measuring total triglycerides, LDL and HDL cholesterol may not be fully accepted clinically relevant lipid abnormalities in uremia, such as the increase in Lp (a), IDL cholesterol, modifying LDL cholesterol and changes in HDL cholesterol sub fraction.
Results of testing the found in the average evaluation of blood clots for the heparin tested periods at the beginning of the study was statistically signifi cant, but at the end of the study was not statistically signifi cant diff erences. At the beginning of the study standard heparin had a signifi cant better eff ect on anticoagulation eff ects of blood in men than in women, while after one year follow-up of patients was not statistically signifi cant differences. LWMH at the beginning of the study had a far better evaluate the leaching system, and a small degree of clotting in the system, medicine dropper and dialysator of heparin. However, during the study, as well as its very end, the diff erence was no longer statistically significant, so that the end results were almost equal (,) . Given the diff erence between the genders and the type of received anticoagulant diff erences were statistically very signifi cant, so that groups of women treated with heparin had low-improving results dialysis rinsing system, dyalisator and arterial and vein dropper at the end of the study.() e men treated with LWMH, there was a deterioration of results leaching of dialysis, dialysat and system dropper. Rate of low-blood clotting heparin for the fi rst time tracking the men had an average mark ,, while women had an average mark , (lower is better). After a year of follow-up, men who were treated with enoxaparin had an average mark clot, which amounted to ,, while the average grade for women amounted to , (lower is better). Thus the overall assessment of statistical signifi cantly by gender which was signifi cant for the fi rst six months of study, with the level of reliability p≤,, while the second period tracking results also mainly negative, with a confi dence level of p ,. The difference between both periods for men was ,, and , for women and a total of ,, all statistically signifi cant with a confi dence level of p ,. At the beginning of the study, all patients who started treatment hemodialysis with LMWH had better results in terms of better rinsing dialysat and systems, and better effects on the increase in HDL cholesterol and triglyceride values fall in the blood. But at the end of the study results show no signifi cant difference between LWMH and standard heparin () .
Conclusions
e results of our research showed that the LWMH had a better eff ect of leaching of the system and dialysator in both sex equally, in comparesment with the standard heparin. LWMH in women dialysis population led to the improvement of lipid profi les. Patients treated with standard heparin had a statistically signifi cant reduction assessment of blood clots than patients who received enoxaparin (LWMH). LWMH is a good choice for anticoagulation. Found that the long-term treatment with LMWH causes gradual, not abrupt increase in the concentration of serum triglyceride and cholesterol in hemodialysis patients, in contrast to the marked hyperlipidemia as evidenced by long-term use of standard heparin present in most dialysis patients. Many factors have aff ect on the lipid profi le of which is signifi cant to note food that the patients according to its structure is very varied during the twelve months as the time of this research. ese minimal diff erences LWMH and standard heparin can be attributed to the fact that it is still LWMH derivative of standard heparin. Nephrologists', and general practitioners must recognize dyslipedimia in the early stages of HBI, which has developed guidelines to the general population. It is signifi cant to note that our study short time to eff ectuate the complete and detailed analysis of lipid profi les in patients on chronic hemodialysis treatment. Improvement of lipid profi le in dialysis patients will certainly contribute to reducing the risk of cardiovascular complications in hemodialysis patients. 
